Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Last-resort drug offered to brain cancer patients with no options left

NCT ID NCT06404034

First seen Mar 09, 2026 · Last updated Apr 30, 2026 · Updated 6 times

Summary

This program provides an experimental drug called gallium maltolate (GaM) to adults with glioblastoma, a severe brain cancer, that has returned or not responded to standard treatments. It is for patients aged 18 and older who have run out of other options and may still benefit. The goal is to offer compassionate access to this oral medication under a doctor's supervision.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cancer Partners of Nebraska

    Lincoln, Nebraska, 68516, United States

  • Northwell Health

    New York, New York, 10075, United States

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

Conditions

Explore the condition pages connected to this study.